Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timed Sequential Busulfan + Fludarabine in Allo-SCT
NCT01572662Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2012
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Chronic Myeloid Leukemia (CML) and 6 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Non-Relapse Mortality Rate at 100 days. Started Apr 2012; status: completed.
02
Drugs
busulfan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia (CML)chronic lymphocytic leukemia (CLL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01572662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572662.